KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Other Non-Current Liabilities (2016 - 2022)

Historic Other Non-Current Liabilities for Inovio Pharmaceuticals (INO) over the last 14 years, with Q3 2022 value amounting to $710348.0.

  • Inovio Pharmaceuticals' Other Non-Current Liabilities rose 100747.88% to $710348.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $710348.0, marking a year-over-year increase of 100747.88%. This contributed to the annual value of $14826.0 for FY2021, which is 7428.85% down from last year.
  • Inovio Pharmaceuticals' Other Non-Current Liabilities amounted to $710348.0 in Q3 2022, which was up 100747.88% from $14826.0 recorded in Q4 2021.
  • Over the past 5 years, Inovio Pharmaceuticals' Other Non-Current Liabilities peaked at $119.8 million during Q2 2020, and registered a low of $14826.0 during Q4 2021.
  • In the last 5 years, Inovio Pharmaceuticals' Other Non-Current Liabilities had a median value of $87333.0 in 2018 and averaged $9.2 million.
  • Per our database at Business Quant, Inovio Pharmaceuticals' Other Non-Current Liabilities soared by 23589542.97% in 2020 and then crashed by 9994.65% in 2021.
  • Over the past 5 years, Inovio Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $87333.0 in 2018, then surged by 9998.16% to $8.8 million in 2019, then crashed by 99.35% to $57663.0 in 2020, then plummeted by 74.29% to $14826.0 in 2021, then soared by 4691.23% to $710348.0 in 2022.
  • Its Other Non-Current Liabilities was $710348.0 in Q3 2022, compared to $14826.0 in Q4 2021 and $64141.0 in Q3 2021.